Fampridine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), HAS (France) and SMC (Scotland) recommended or restricted fampridine, while PHARMAC (New Zealand) and ZIN (Netherlands) did not recommend it.
The file has been open for more than a decade: 13 years separate the first record, 11 Apr 2012 at HAS (France), from the most recent, 23 Apr 2025 at HAS (France).
TLV (Sweden) changed its position: not recommended on 28 Jun 2012, recommended by 31 Oct 2018, after a resubmission.
No assessment is on file from PBAC (Australia) and CIPM (Spain), each among the eight highest-volume agencies here.
HAS (France) was first to assess fampridine, on 11 Apr 2012; NYE METODER (Norway) did not open a file until 21 Mar 2021 — an unusually long tail of 8.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 8 agencies here assessed fampridine more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for fampridine.
The full ledger for fampridine reads 6 not recommended, 5 recommended, 3 other and 1 no benefit.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 23 Apr 2025 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| NYE METODER (Norway) | 21 Mar 2021 | Bedring av gangfunksjonen hos voksne pasienter med multippel sklerose (MS) og problemer med å gå (EDSS 4-7) | decision recorded | source |
| SMC (Scotland) | 13 Apr 2020 | For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7). | accepted | source |
| AWMSG (Wales) | 12 Dec 2019 | Improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Sca… | recommended (full) | source |
| ZIN (Netherlands) | 7 Aug 2019 | GVS-advies fampridine (Fampyra®) voor een subgroep van patiënten met multiple sclerose (MS) | not reimbursed (GVS) | source |
10 further decisions for fampridine, across 5 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- tafamidis — same ATC class N07X — Other nervous system
- vutrisiran — same ATC class N07X — Other nervous system
- pitolisant — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- patisiran — same ATC class N07X — Other nervous system
- tofersen — same ATC class N07X — Other nervous system
Coverage: 15 decisions for fampridine from 8 agencies, 2012 to 2025. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.